Sharon Engel, Ph.D., Senior Director and Head of Pharmacology, is responsible for the advancement of the Delix Therapeutics psychedelic-inspired drug discovery programs from initiation to IND filings.

Sharon brings over 15 years of drug discovery experience in the pharmaceutical industry with a focus on neuroscience and psychiatry.  She has successfully led multiple projects from idea inception to the clinic. She is an expert in the development of translational biomarker strategies and has contributed to multiple IND’s. Sharon has also been instrumental in contributing to patent applications.

Sharon received formal education in Physiology (B.A. and M.S.), Biomedical Sciences (Ph.D.), and post-doctoral fellowships at the National Institute of Mental Health.